Revenue totaled $17.77 billion, up 1.6 percent but below Street forecasts for $18.01 billion. In late-morning trading, J&J shares dropped $4.62, or 3.7 percent, to $121.10. Sales in J&J’s prescription drug business rose 0.8 percent to $8.3 billion. But top seller Remicade, an injected biologic drug for Crohn’s disease, rheumatoid arthritis and other immune disorders, saw sales decrease 6 percent to $1.7 billion. Near copy, or “biosimilar,” versions of Remicade have cut into its sales in Europe, where they’ve been available for much longer than in the U.S. Caruso said the launch late last year of Pfizer Inc.’http://christianrichardsonplus.accessnetwork.us/2017/04/19/identifying-methods-in-course-for-interview/s Inflectra, a biosimilar of Remicade, has had little impact on sales in the U.S. Doctors there are hesitant to prescribe biosimilars, which are relatively new to the U.S. market, for patients doing well on Remicade. The Tylenol maker’s consumer product sales rose 1 percent to $3.3 billion, while sales of medical devices and diagnostic equipment increased 3 percent to $6.3 billion. “The company performed mediocrely in two key areas pharmaceuticals and consumer products. It managed expenses well, but to continue to increase profits, it has to generate better sales increases,” Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan’s Ross School of Business, wrote in an email.
For the original version including any supplementary images or video, visit https://www.yahoo.com/news/johnson-johnson-tops-1q-profit-105620623.html